Subscribe
shutterstock_1696929460_m_foto
M-Foto / Shutterstock.com
27 April 2021Big PharmaRory O'Neill

Counterfeiters ‘exploiting demand’ for COVID-19 vaccines

Pfizer has discovered counterfeit versions of its COVID-19 vaccine in Mexico and Poland, prompting governments to reassure the public over the safety of vaccine supply chains.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
EU backs compulsory licensing for COVID vaccines
8 June 2021   The European Union has submitted a new proposal to the World Trade Organisation, which backs compulsory licensing agreements for COVID-19 vaccines when negotiations fail.
Big Pharma
Ghana in licensing talks to manufacture AstraZeneca vaccine
27 April 2021   Ghana’s pharmaceutical industry has asked AstraZeneca about acquiring rights to produce its COVID vaccine locally, buoying the country’s inoculation efforts.
Big Pharma
EU concludes COVID-19 vaccine talks with Pfizer
10 September 2020   The European Commission has concluded exploratory talks with Pfizer and BioNTech to potentially supply 300 million doses of their investigational vaccine against COVID-19.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Europe
EU backs compulsory licensing for COVID vaccines
8 June 2021   The European Union has submitted a new proposal to the World Trade Organisation, which backs compulsory licensing agreements for COVID-19 vaccines when negotiations fail.
Big Pharma
Ghana in licensing talks to manufacture AstraZeneca vaccine
27 April 2021   Ghana’s pharmaceutical industry has asked AstraZeneca about acquiring rights to produce its COVID vaccine locally, buoying the country’s inoculation efforts.
Big Pharma
EU concludes COVID-19 vaccine talks with Pfizer
10 September 2020   The European Commission has concluded exploratory talks with Pfizer and BioNTech to potentially supply 300 million doses of their investigational vaccine against COVID-19.

More on this story

Europe
EU backs compulsory licensing for COVID vaccines
8 June 2021   The European Union has submitted a new proposal to the World Trade Organisation, which backs compulsory licensing agreements for COVID-19 vaccines when negotiations fail.
Big Pharma
Ghana in licensing talks to manufacture AstraZeneca vaccine
27 April 2021   Ghana’s pharmaceutical industry has asked AstraZeneca about acquiring rights to produce its COVID vaccine locally, buoying the country’s inoculation efforts.
Big Pharma
EU concludes COVID-19 vaccine talks with Pfizer
10 September 2020   The European Commission has concluded exploratory talks with Pfizer and BioNTech to potentially supply 300 million doses of their investigational vaccine against COVID-19.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB